<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24566025</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1776-2561</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>70</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <MedlineDate>2014 Feb-Apr</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Revue de pneumologie clinique</Title>
                <ISOAbbreviation>Rev Pneumol Clin</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].</ArticleTitle>
            <Pagination>
                <MedlinePgn>38-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pneumo.2013.12.005</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0761-8417(14)00005-4</ELocationID>
            <Abstract>
                <AbstractText>Recent advances in the molecular characterization of metastatic unresectable lung cancers have markedly improved the management of patients. Today, molecular tests should be performed routinely in all patients with non-squamous non-small cell lung cancer, and in case of squamous cell carcinoma occurring in a non-smoker. In the presence of EGFR mutation or ALK rearrangement, specific inhibitors have shown superior efficacy to chemotherapy in first-line treatment for anti-EGFR (erlotinib and gefitinib) and in second-line treatment for anti-ALK (crizotinib). We will report the most recent clinical trials that aimed to identify effective therapeutic alternatives in case of acquired resistance to first-generation inhibitors (erlotinib, gefitnib, crizotinib), which inevitably occur in a median of 11-13 months at the first line setting and 7 months at the second line setting. Finally, we will describe more recently known molecular alterations such as ROS1 or RET rearrangements and HER2, BRAF, PIK3CA, DDR2 mutations. Some of these alterations are already elegible for dedicated targeted therapies within clinical trials or temporary use authorization (ATU). </AbstractText>
                <CopyrightInformation>Copyright © 2014. Published by Elsevier Masson SAS.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pecuchet</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France; Unité Inserm U775 : bases moléculaires de la réponse aux xénobiotiques, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bigot</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henni</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabre</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'oncologie médicale, hôpital européen Georges-Pompidou, 20-30, rue Leblanc, 75908 Paris cedex 15, France; Unité Inserm U775 : bases moléculaires de la réponse aux xénobiotiques, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France. Electronic address: elizabeth.fabre@egp.aphp.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Impact thérapeutique du diagnostic moléculaire des carcinomes bronchiques non à petites cellules métastatiques : les traitements ciblés en 2013.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>02</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Rev Pneumol Clin</MedlineTA>
            <NlmUniqueID>8406312</NlmUniqueID>
            <ISSNLinking>0761-8417</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>53AH36668S</RegistryNumber>
                <NameOfSubstance UI="D000077547">Crizotinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DA87705X9K</RegistryNumber>
                <NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S65743JHBS</RegistryNumber>
                <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077547" MajorTopicYN="N">Crizotinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D025202" MajorTopicYN="Y">Molecular Diagnostic Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer bronchique non à petites cellules métastatiques non résécable</Keyword>
            <Keyword MajorTopicYN="N">Drug resistance</Keyword>
            <Keyword MajorTopicYN="N">Fusion de gènes</Keyword>
            <Keyword MajorTopicYN="N">Gene fusion</Keyword>
            <Keyword MajorTopicYN="N">Molecular targeted therapy</Keyword>
            <Keyword MajorTopicYN="N">Mutation</Keyword>
            <Keyword MajorTopicYN="N">Résistance aux traitements</Keyword>
            <Keyword MajorTopicYN="N">Thérapies moléculaires ciblées</Keyword>
            <Keyword MajorTopicYN="N">Unresectable metastatic non-small cell lung cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24566025</ArticleId>
            <ArticleId IdType="pii">S0761-8417(14)00005-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pneumo.2013.12.005</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>